Venous Thromboembolism in Patients Undergoing Primary Pancreatic Tumour Resection; a Prospective Observational Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 64
- 试验地点
- 1
- 主要终点
- Fibrinogen-VTE
研究概览
简要总结
This study will evaluate the development of venous thromboembolism (VTE) and possible determinants in patients with primary pancreatic cancer undergoing pancreatic cancer resection.
详细描述
Cancer associated thrombosis (CAT) is the second cause of death, in oncologic patients after tumour progression itself. Patients suffering from malignancies are at increased risk for both venous (4-20%) and arterial (2-5%) thrombotic events. Moreover, cancer is one of the most important acquired risk factors for the development of venous thromboembolism (VTE).
Pancreatic cancer is the fourth most deadly cancer world-widely and has been recognised as the most prothrombotic malignancy, with a reported incidence of VTE (8-18%), followed by renal and ovarian cancer (VTE 5.6%). Although the exact pathophysiological mechanisms are still poorly understood it seems that pancreatic cancer induces a prothrombotic and hypercoagulable state.
Aims
- To evaluate the predictive value of preoperatively or early postoperatively obtained NLR, in patients with primary pancreatic cancer undergoing pancreatic cancer resection, for VTE up to the 30rd postoperative day
- To evaluate the predictive value of preoperatively or early postoperatively obtained coagulation biomarkers/parameters, in patients with primary pancreatic cancer undergoing pancreatic cancer resection, for VTE up to the 30rd postoperative day
- To evaluate the incidence of VTE in patients with primary pancreatic cancer undergoing pancreatic cancer resection
- To assess the perioperative coagulation status of patients with primary pancreatic cancer undergoing pancreatic cancer resection
- To evaluate any possible determinant or predictive factor for VTE among the coagulation parameters or patients' baseline characteristics
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Consecutive pancreatic cancer patients undergoing pancreatic cancer resection in University Hospital of Larissa, after informed consent will be included.
排除标准
- •Refuse to participate
- •Previous thromboembolic event < 6 months prior to the operation
- •History of inherited or acquired bleeding disorder
- •ASA PS > 3
- •Concomitant presence of a second primary malignancy
- •Unresectable pancreatic cancer
结局指标
主要结局
Fibrinogen-VTE
时间窗: up to 30rd postoperative day
The predictive value of preoperatively or early (10th day) postoperatively obtained, fibrinogen, in patients with primary pancreatic cancer undergoing pancreatic cancer resection, for VTE up to the 30rd postoperative day
von Willebrand factor-VTE
时间窗: up to 30rd postoperative day
The predictive value of preoperatively or early (10th day) postoperatively obtained von Willebrand factor in patients with primary pancreatic cancer undergoing pancreatic cancer resection, for VTE up to the 30rd postoperative day
D-dimers-VTE
时间窗: up to 30rd postoperative day
The predictive value of preoperatively or early (10th day) postoperatively obtained, D-dimers, in patients with primary pancreatic cancer undergoing pancreatic cancer resection, for VTE up to the 30rd postoperative day
Factors VIII and XI-VTE
时间窗: up to 30rd postoperative day
The predictive value of preoperatively or early (10th day) postoperatively obtained factors VIII and XI in patients with primary pancreatic cancer undergoing pancreatic cancer resection, for VTE up to the 30rd postoperative day
Neutrophil to lymphocyte ratio-VTE
时间窗: up to 30rd postoperative day
The predictive value of preoperatively or early (10th day) postoperatively obtained neutrophil to lymphocyte ratio (NLR), in patients with primary pancreatic cancer undergoing pancreatic cancer resection, for VTE up to the 30rd postoperative day
Adams-13-VTE
时间窗: up to 30rd postoperative day
The predictive value of preoperatively or early (10th day) postoperatively obtained adams-13 in patients with primary pancreatic cancer undergoing pancreatic cancer resection, for VTE up to the 30rd postoperative day
VTE incidence in primary pancreatic cancer resection
时间窗: up to 30rd postoperative day
The incidence of VTE in patients with primary pancreatic cancer undergoing pancreatic cancer resection
次要结局
未报告次要终点
研究者
Elena Arnaoutoglou
Professor of Anaesthesiology
University of Thessaly
